Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

CHIBUZO CHUKWUNONSO OKOYE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1659831469
CMS profile
11390348
Location
BROOKLYN, NY

General Payments · PY2022–2024

$2,489.30

  • Reported across 33 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,588.88

15 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,181.02 5
Food and Beverage $407.86 10

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $1,379.28 10
Acerta Pharma LLC $150.63 2
Aurinia Pharma U.S., Inc. $36.42 2
AKEBIA THERAPEUTICS INC $22.55 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $297.28 4
PY2023 $603.14 14
PY2024 $1,588.88 15

Payment records · PY2024 (15)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AKEBIA THERAPEUTICS INC $22.55 06/21/2024 Food and Beverage Undisputed 01/23/2026 1145825585 CMS
AstraZeneca Pharmaceuticals LP $124.31 01/24/2024 Food and Beverage Undisputed 01/23/2026 1105657800 CMS
AstraZeneca Pharmaceuticals LP $26.32 02/22/2024 Food and Beverage Undisputed 01/23/2026 1105704546 CMS
Aurinia Pharma U.S., Inc. $14.58 02/20/2024 Food and Beverage Undisputed 01/23/2026 1150688851 CMS
Aurinia Pharma U.S., Inc. $21.84 05/14/2024 Food and Beverage Undisputed 01/23/2026 1150688853 CMS
GlaxoSmithKline, LLC. $438.48 12/03/2024 Travel and Lodging Undisputed 01/23/2026 1115840223 CMS
GlaxoSmithKline, LLC. $31.02 12/03/2024 Travel and Lodging Undisputed 01/23/2026 1116042271 CMS
GlaxoSmithKline, LLC. $31.02 12/03/2024 Travel and Lodging Undisputed 01/23/2026 1116265846 CMS
GlaxoSmithKline, LLC. $438.48 12/03/2024 Travel and Lodging Undisputed 01/23/2026 1116612590 CMS
GlaxoSmithKline, LLC. $242.02 12/09/2024 Travel and Lodging Undisputed 01/23/2026 1116042041 CMS
GlaxoSmithKline, LLC. $78.84 12/10/2024 Food and Beverage Undisputed 01/23/2026 1115750024 CMS
GlaxoSmithKline, LLC. $24.35 12/10/2024 Food and Beverage Undisputed 01/23/2026 1116021401 CMS
GlaxoSmithKline, LLC. $32.46 12/10/2024 Food and Beverage Undisputed 01/23/2026 1116245683 CMS
GlaxoSmithKline, LLC. $6.96 12/10/2024 Food and Beverage Undisputed 01/23/2026 1116451639 CMS
GlaxoSmithKline, LLC. $55.65 12/10/2024 Food and Beverage Undisputed 01/23/2026 1116526038 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.